Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).

NCT01704781 is registered in ClinicalTrials.gov with Bionor Immuno AS as lead sponsor.

NCT NCT01704781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01704781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).
Lead sponsor
Bionor Immuno AS
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2012
Completion date
August 31, 2014
Enrollment
36 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection